Povorcitinib in Phase 3 Hidradenitis Suppurativa Trials

• by Kathryn Wighton

• August 6, 2026

Reorganization and functional divergence of the CD4+ memory T cell compartment in hidradenitis suppurativa

• by Laura Casals-Diaz, Jorge Romaní, Abir Ezzaanouni, Madalina Raducu, Cristina Vila, Lluís Boix, Amadeu Gavaldà, Antonio Guilabert

• July 14, 2026

Financial Impact of Hidradenitis Suppurativa in Spain

• by Eva Vilarrasa, Joaquín Borrás-Blasco, Silvia Lobo-Benito, Marta Loro-Pérez, Marta Garcia Núñez-García, Juan Oliva-Moreno, David Palacios-Martínez, Félix Rubial-Bernárdez, Yoana Ivanova-Markova, Mathilde Daheron, Javier Bellas, Antonio Martorell

• February 22, 2026

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

Secukinumab becomes the only interleukin-17A inhibitor approved for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.

• by Kathryn Wighton

• March 13, 2026

• 2 min